Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary ...
Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12) Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM ET NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- …